Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.79 |
| ▸ | HTR1A | P08908 | 3/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.79 |
| ▸ | HTR2A | P28223 | 3/20 | 0.79 |
| ▸ | HRH1 | P35367 | 3/20 | 0.79 |
| ▸ | DRD4 | P21917 | 3/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.79 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.79 |
| ▸ | HTR2B | P41595 | 2/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moperone SCHEMBL365007 | 0.99 | DRD2 (0.98) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20248952 | 0.94 | DRD2 (0.88) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL9054984 | 0.94 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL9053091 | 0.89 | DRD2 (0.84) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL11796046 | 0.88 | DRD2 (0.88) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| Haloperidol SCHEMBL5070670 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| Bromperidol SCHEMBL43755 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20653047 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20254453 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20248954 | 0.88 | DRD2 (0.79) | DRD2DRD3ADRA1AHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. | 2025-05-08 | — | — | US | claimed |
| US-12102640-B2 | Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-10-01 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| US-11478482-B2 | Fasudil for the treatment of schizophrenia | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIG (JP) | 2022-10-25 | — | — | US | claimed |
| EP-0969845-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | Akzo Nobel N.V. (NL) | 2000-01-12 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1995032981-A1 | NOVEL GLYCOSIDE COMPOUNDS AND PRODUCTION AND USE THEREOF | HARRIER, INC. (US) | 1995-12-07 | — | — | WO | claimed |
| EP-0441333-B1 | Pharmaceutical composition | SHOWA PHARM CHEM IND (JP) | 1994-05-11 | — | — | EP | claimed |
| US-5118508-A | Butyrophenone compound; vehicle of polyvinyl acetal diethylaminoacetate and polyvinyl pyrrolidone; cataplasm, treatment of vomitting and schizophreneia | SHOWA YAKUHIN KAKO CO., LTD. (JP) | 1992-06-02 | — | — | US | claimed |
| EP-0441333-A1 | Pharmaceutical composition | SHOWA YAKUHIN KAKO CO., LTD. (JP) | 1991-08-14 | — | — | EP | claimed |
| EP-0305008-A2 | Tumor or cancer cell killing therapy and agents useful therefor | OXI-GENE, INC. (US) | 1989-03-01 | — | — | EP | claimed |
| US-4565821-A | 4-PIPERADINO-4*-FLUOROBUTYROPHENONES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1986-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | DRD2 2127/4885DRD3 2303/4885ADRA1A 263/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | DRD2 4836/4885DRD3 4793/4885ADRA1A 3373/4885 |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | GRIN2B, DRD2, SLC6A3 | DRD2 2/4885DRD3 11/4885ADRA1A 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.